For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...